Phase II trial of telaprevir in patients with HCV who have CC genetic marker.

Trial Profile

Phase II trial of telaprevir in patients with HCV who have CC genetic marker.

Planning
Phase of Trial: Phase II

Latest Information Update: 29 Jul 2011

At a glance

  • Drugs Peginterferon alfa-2a; Ribavirin; Telaprevir
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 29 Jul 2011 Planned number of patients changed to approximately 400.
    • 29 Jul 2011 Planned initiation date changed from 1 Jul 2011 to 1 Aug 2011.
    • 17 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top